Project Grant R01HL180871
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $190,998 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). The 5-year grant will fund a research project titled "Understanding Pulmonary Fibrosis Through the Integration of Complex Occupational and Environmental Exposure Assessments (PF-OEM)." The project aims to use epidemiological tools to...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,568.00 to The Leland Stanford Junior University (Stanford University) to conduct research aimed at disaggregating and spatially profiling early-stage lung fibrosis microenvironments. The overarching goal is to utilize spatial biology and biomaterial modeling techniques to uncover the cellular and molecular drivers of early fibrogenesis in interstitial...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research on how tissue elasticity and viscosity modulate the signaling between macrophages and fibroblasts in cardiac fibrosis. The $231,552 award, granted to the University of California, San Diego, will fund research to investigate the effects of mechanical stimuli on macrophage-fibroblast interactions and explore the role of a changing mechanical...
- This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...
- The National Heart Lung and Blood Institute awarded a $719,882 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to elucidate lung-specific immune pathways driving post-hematopoietic cell transplant lung injury in children. The research aims to identify cellular and molecular targets for precision diagnostics and therapeutics. Specifically, the project will leverage bronchoalveolar lavage fluid...
- The National Heart Lung and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $172,724 project grant to The Regents of the University of California, San Francisco (UCSF) on February 28, 2025. The grant supports research to investigate the epigenetic signatures and gene regulatory networks driving the trans-differentiation of alveolar type II (AT2) cells into airway-like basal cells under homeostatic conditions and in the context of fibrotic...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of purinergic signaling in fibroblast activation and lung fibrosis. The $728,577 grant, awarded to the Regents of the University of California, San Francisco, aims to investigate the mechanisms by which the ATP receptor P2RX4 influences fibrotic pathways in lung fibroblasts. The research seeks to elucidate the...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...